Comparison of outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide: A population-based study

• D.T.S. Woon,
• A. Finelli,
• C.J.D. Wallis,
• C. Douglas,
• L. Martin,
• R. Saskin,
• N. Fleshner

Affiliations

D.T.S. Woon

A. Finelli

C.J.D. Wallis

C. Douglas

L. Martin

R. Saskin

N. Fleshner